Surgeries & Interventions

Interventional Cardiology Joins The Match for 2025

Prospective interventional cardiology fellows can breathe a sigh of relief. Starting in 2025, three-quarters of interventional cardiology fellowship programs will transition to a voluntary match system.

“The Match” uses an algorithm to place resident and fellowship applicants into their most preferred programs that also prefer them. 

  • While all other CV specialty fellowships already use a match system to place candidates, IC has been the lone exception. That will change in the 2024-2025 application cycle. 

The Society for Cardiovascular Angiography and Interventions (SCAI) initiated the change, hoping that the match system will promote “fairness, equity, and thoughtfulness.” 

  • Of the 177 accredited IC training programs, 136 signed on to SCAI’s initiative in support of the match– just surpassing the 75% threshold needed to change the precedent.

The current system, which will be phased out in 2024, can be chaotic and anxiety-inducing for applicants. There is no central information hub to find out key details about available programs and positions, which prompts both the applicants and programs to waste a lot of effort.

  • When a candidate is offered a position, they have a certain amount of time to either accept or decline the offer – sometimes as little as 48 hours – and often don’t have the opportunity to complete interviews at other institutions. Cardiologists have made it clear that they hate this. 

The Takeaway

The Match should help shift the decision-making power in favor of the candidate, rather than the program. In the next couple of years, candidates will have the opportunity to interview and assess the programs that might best meet their professional, personal, and logistic objectives without the pressure of an unreasonable deadline to commit.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiology Business June 19, 2025

Lilly Buys Verve, Bringing Gene Editing Mainstream June 19, 2025

Gene editing for heart disease just got a major boost as Eli Lilly acquired Verve Therapeutics and its one-dose cholesterol drugs for up to $1.3B, marking a new path for Verve’s therapies to go mainstream. Part of the acquisition likely stems from Verve’s recent impressive trial results for its PCSK9-blocking treatment, VERVE-102, which lowered LDL-C […]

Cardiac Imaging June 19, 2025

New AI-driven Tool Aids in Mitral Valve Assessment June 19, 2025

By: Jimmy Su, Ph.D. Principal Scientist, Cardiovascular Ultrasound, Philips A new tool, Automated 3D Color Flow Quantification (3D Auto CFQ), removes the reliance on assumptions when quantifying mitral regurgitation and replaces it with a reliable and robust, AI-driven method that delivers precise measurement of mitral valve regurgitant volume (RVol) regardless of orifice shape and size. Eliminating assumptions: Quantification […]

Cardiology Pharmaceuticals June 16, 2025

No Need to Discontinue Abelacimab Pre-Procedure June 16, 2025

A new analysis of AZALEA-TIMI 71 suggests Anthos Therapeutics’ abelacimab is capable of reducing major bleeding in patients with AFib undergoing invasive procedures. The sub-analysis examined a total of 920 procedures across 441 patients taking either abelacimab or rivaroxaban, with approximately 1-in-3 patients undergoing an invasive procedure over a median follow-up of 2.1 years. Researchers […]

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!